NASDAQ:FLXNFlexion Therapeutics Stock Price, Forecast & News

Flexion Therapeutics' stock was trading at $12.31 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, FLXN shares have decreased by 21.3% and is now trading at $9.69. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Flexion Therapeutics.

Flexion Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Flexion Therapeutics.

Flexion Therapeutics Inc (NASDAQ:FLXN) released its quarterly earnings results on Thursday, May, 7th. The specialty pharmaceutical company reported ($0.95) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.00) by $0.05. The specialty pharmaceutical company earned $20.13 million during the quarter, compared to analysts' expectations of $18.45 million. Flexion Therapeutics had a negative net margin of 175.76% and a negative return on equity of 592.50%. View Flexion Therapeutics' earnings history.

9 Wall Street analysts have issued twelve-month price targets for Flexion Therapeutics' shares. Their forecasts range from $17.00 to $35.00. On average, they anticipate Flexion Therapeutics' share price to reach $23.33 in the next twelve months. This suggests a possible upside of 140.8% from the stock's current price. View analysts' price targets for Flexion Therapeutics.

Media headlines about FLXN stock have been trending extremely negative this week, according to InfoTrie. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Flexion Therapeutics earned a news sentiment score of -4.0 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutFlexion Therapeutics.

Flexion Therapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 8,200,000 shares, an increase of 15.5% from the April 15th total of 7,100,000 shares. Based on an average daily volume of 766,100 shares, the short-interest ratio is presently 10.7 days. Approximately 25.6% of the shares of the stock are short sold. View Flexion Therapeutics' Current Options Chain.

Some companies that are related to Flexion Therapeutics include Intra-Cellular Therapies (ITCI), Akcea Therapeutics (AKCA), Innoviva (INVA), Amneal Pharmaceuticals (AMRX), Passage Bio (ZNTL), Portola Pharmaceuticals (PTLA), Tricida (TCDA), Cytokinetics (CYTK), Supernus Pharmaceuticals (SUPN), ZEALAND PHARMA/S (ZEAL), MacroGenics (MGNX), Revance Therapeutics (RVNC), Phoenix Tree (IMAB), Esperion Therapeutics (ESPR) and Phathom Pharmaceuticals (PHAT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Cara Therapeutics (CARA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Aduro BioTech (ADRO), Synergy Pharmaceuticals (SGYP), Verastem (VSTM), Inovio Pharmaceuticals (INO), Micron Technology (MU) and NVIDIA (NVDA).

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Flexion Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.71%), Wasatch Advisors Inc. (6.01%), State Street Corp (4.30%), Gagnon Securities LLC (1.88%), Granahan Investment Management Inc. MA (1.83%) and Schroder Investment Management Group (1.64%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, David Arkowitz, Mark S Levine, Michael D Clayman, Neil Bodick and Samuel D Colella. View institutional ownership trends for Flexion Therapeutics.

FLXN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Spark Investment Management LLC, UBS Group AG, State Street Corp, Gagnon Securities LLC, Parametric Portfolio Associates LLC, Victory Capital Management Inc., and Victory Capital Management Inc.. View insider buying and selling activity for Flexion Therapeutics.

FLXN stock was purchased by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Nuveen Asset Management LLC, Wasatch Advisors Inc., Two Sigma Investments LP, Raymond James Financial Services Advisors Inc., New York State Common Retirement Fund, Paradigm Capital Management Inc. NY, and Mesirow Financial Investment Management Inc.. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, David Arkowitz, Michael D Clayman, and Samuel D Colella. View insider buying and selling activity for Flexion Therapeutics.

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FLXN stock can currently be purchased for approximately $9.69.

Flexion Therapeutics has a market capitalization of $373.68 million and generates $72.96 million in revenue each year. The specialty pharmaceutical company earns $-149,770,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Flexion Therapeutics employs 288 workers across the globe.

The official website for Flexion Therapeutics is www.flexiontherapeutics.com.

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]